Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageWe are a leading, full service, non-clinical global drug development partner with a mission to create healthier lives. We have built upon our original core competency of laboratory animal medicine and science (research model technologies) to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, that supports our clients from target identification through non-clinical development.
In the company’s own words · 10-K filed Feb 18, 2026 · SEC EDGAR
Business segments
Q2 2026 · $785.2MThe company’s own SEC segment disclosure.
- Discovery And Safety Assessment$605.9M77%
- Research Models And Services$94.4M12%
- Manufacturing Support$84.9M11%
Charles River Laboratories (CRL) reported revenue of $1.00B in Q2 2026 (quarter ended June 27, 2026), down 2.7% from the same quarter a year earlier. That came with net loss of $1.5M. For the full year FY2025, revenue was $4.02B (−0.9% year on year) and net income −$144M. Its largest segment in 2026-Q2 was Discovery And Safety Assessment at $606M, 77% of the disclosed total, just ahead of Research Models And Services at 12%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
Ranks #17 of 29 by Smart Score